Pharmaceutical Healthcare Deals & Acquisitions - 2026 | iPharmaCenter

LEO Pharma Acquires Dersimelagon Rights in Rare Dermatology Deal

LEO Pharma has agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma in a transaction that could be worth up to $435 million in upfront and near-term milestone payments.

The deal adds a late-stage oral medicine to LEO Pharma’s rare dermatology pipeline and strengthens the company’s focus on genetic skin diseases with limited treatment options. Tanabe Pharma will also be eligible for potential future milestone payments and tiered royalties based on net sales.

Candidate Targets Two Rare Disorders

Dersimelagon is an investigational, once-daily oral melanocortin 1 receptor agonist being developed for erythropoietic protoporphyria and X-linked protoporphyria.

Both conditions are lifelong genetic disorders that can cause intense pain after exposure to sunlight. Patients may also experience skin redness, swelling, rashes, burning sensations, and other phototoxic reactions. In some cases, the diseases can affect the liver.

The medicine is designed to increase melanin levels in the skin. By increasing pigmentation, dersimelagon may reduce the amount of sunlight reaching sensitive tissues and help limit sunlight-triggered reactions.

FDA Review Is Underway

Tanabe Pharma submitted a New Drug Application to the US Food and Drug Administration on June 30, 2026. Dersimelagon has received both Fast Track and Orphan Drug designations from the FDA.

The candidate has not yet been approved by the FDA or any other regulatory authority. Its safety and effectiveness therefore remain under regulatory review.

If cleared, dersimelagon could become the first oral treatment specifically approved for erythropoietic protoporphyria and X-linked protoporphyria, potentially addressing a significant gap in rare disease care.

Phase 3 Study Supports Development

The acquisition follows positive results from the global Phase 3 INSPIRE study. The randomized, double-blind, placebo-controlled trial evaluated dersimelagon in patients with erythropoietic protoporphyria and X-linked protoporphyria.

Tanabe Pharma reported statistically significant and clinically meaningful results across the study’s primary and secondary measures. One important finding was a longer average period of sunlight exposure before patients developed early warning symptoms.

The Phase 3 findings were presented during a late-breaking session at the 2026 annual meeting of the American Academy of Dermatology.

Adds to LEO Pharma’s External Innovation Strategy

LEO Pharma has been expanding its medical dermatology pipeline through acquisitions, licensing arrangements, and research partnerships.

The dersimelagon agreement follows the company’s acquisition of Replay’s next-generation herpes simplex virus gene therapy platform and its partnership with Boehringer Ingelheim involving spesolimab.

Together, these transactions indicate a broader strategy focused on rare and serious skin diseases where patients have limited treatment choices. LEO Pharma identified the United States and Japan as important markets for advancing innovative dermatology products.

Commercial and Regulatory Outlook

The acquisition gives LEO Pharma access to a Phase 3 completed asset with an active US regulatory application. The company’s potential launch timeline will depend on the FDA’s review and the outcome of any additional regulatory requirements.

Dersimelagon’s oral, once-daily dosing could offer a practical advantage for patients who currently have limited options for preventing sunlight-related symptoms. However, the medicine’s final clinical value, safety profile, and commercial prospects will depend on regulatory decisions and post-approval evidence.

The transaction is expected to close during the second half of 2026.